Long-Term Follow-up of Survival in Hodgkin's Lymphoma

Abstract

To the Editor: In 1992, the Cancer and Leukemia Group B (CALGB) reported the results of a prospective three-group randomized trial involving 359 patients with Hodgkin's lymphoma. This trial compared the following regimens: doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for 6 to 8 months, mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) for 6 to 8 months, and MOPP alternating with ABVD for 12 months.1 The trial was limited to patients with advanced disease (clinical stages III and IV). No radiotherapy was administered. The results, published in the Journal in 1992, indicated an event-free survival advantage of ABVD over MOPP but no . . .